Delving into the Latest Updates on BFP-002 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

antibiofilm non-antibiotic(BioFilm Pharma)

Target-

Mechanism-

Therapeutic Areas

Infectious DiseasesCongenital DisordersDigestive System Disorders+ [2]

Active Indication

Community acquired respiratory tract infectionCystic FibrosisPseudomonas Infections+ [2]

Inactive Indication-

Originator Organization

Biofilm PharmaStartup

Active Organization

Biofilm PharmaStartup

Inactive Organization-

Drug Highest PhaseDiscovery

First Approval Date-

Regulation-

Strategies for efficient osteogenic differentiation and bone formation from stem cells would have clinical applications in treating nonunion fracture healing. Many researchers have attempted to develop adjuvants as specific stimulators of bone formation for therapeutic use in patients with bone resorption. Therefore, development of specific stimulators of bone formation has therapeutic significance in the treatment of osteoporosis. To date, investigations of the mature forms of bone morphogenetic proteins (BMPs) have focused on regulation of bone generation. However, we previously identified new peptides from the immature precursor of BMP, and further analysis of these proteins should be performed. In this study, we identified a new peptide called bone-forming peptide-2 (BFP-2), which has stronger osteogenic differentiation-promoting activity than BMP-7. BFP-2 treatment of multipotent bone marrow stromal cells (BMSCs) induced expression of active alkaline phosphatase. In addition, BFP-2 enhanced CD44 and CD51 expression levels and increased Ca²⁺ content in BMSCs. Moreover, radiography at 8 weeks revealed that animals that had received transplants of BFP-2-treated BMSCs showed substantially increased bone formation compared with animals that had received BMSCs treated with BMP-7. Our findings indicate that BFP-2 may be useful in the development of adjuvant therapies for bone-related diseases.

100 Deals associated with BFP-002

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Community acquired respiratory tract infection	Discovery	FR	Biofilm PharmaStartup	-
Cystic Fibrosis	Discovery	FR	Biofilm PharmaStartup	-
Pseudomonas Infections	Discovery	FR	Biofilm PharmaStartup	-
Pulmonary Disease, Chronic Obstructive	Discovery	FR	Biofilm PharmaStartup	-
Staphylococcal Infections	Discovery	FR	Biofilm PharmaStartup	-